CytomX and Regeneron Expand $4B Cancer Immunotherapy Alliance
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 CytomX Therapeutics has announced a significant expansion of its strategic research...
Biopharmaceuticals
Advertisement
Gilead’s Livdelzi Achieves Key Phase 3 PBC Trial Goal
FOSTER CITY, California, USA, June 2, 2026 Gilead Sciences has announced positive topline results from the Phase 3 IDEAL...
Travere Licenses Civorebrutinib in $1.14B Kidney Disease Deal
SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...
Johnson & Johnson’s Nipocalimab Shows Strong SLE Results
LONDON, United Kingdom, June 3, 2026 Johnson & Johnson has announced positive late-breaking results from its Phase 2 JASMINE...
IDEAYA and Roche Advance Targeted Therapy for PDAC
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 IDEAYA Biosciences and Roche have entered into a strategic clinical collaboration...
Advertisements
Antengene Presents First ATG-207 Autoimmune Disease Data at EULAR 2026
SHANGHAI, China, June 3, 2026 Antengene has announced the first preclinical data for ATG-207, its investigational αCD3-TGF-β bifunctional fusion...
Medtronic Expands Hugo Robotic Surgery System with New FDA Filings
GALWAY, Ireland, June 3, 2026 Medtronic has announced a series of major regulatory and clinical milestones aimed at significantly...
DHCG and Altruist Partner to Advance Biologics in China
WALNUT CREEK, California, USA & SUZHOU, China | June 3, 2026 Dark Horse Consulting Group (DHCG) and Altruist Biologics...
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Sanofi’s Venglustat Gains FDA Priority Review for GD3
PARIS, France, May 28, 2026 Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
Advertisement
